India's Dr Reddy's says FDA raises concerns about plant

MUMBAI, Nov 27 (Reuters) - Indian drugmaker Dr Reddy's Laboratories Ltd has received a letter from the U.S. Food and Drug administration highlighting concerns about its manufacturing plant in the southern Indian state of Andhra Pradesh, the company said on Thursday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.